Gilead Sciences (United Kingdom)
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Gilead Sciences (United Kingdom), United Kingdom, covering academic research published from 2001 to 2024. Read More.
Open Access Percentage
64%
Total
Publications
253
Total Open
Publications
161
Total
Citations
5.8K
Open Access
Percentage
64%
Total
Publications
253
Total Open
Publications
161
Total
Citations
5.8K
Breakdown
Publisher Open
24%
Both
33%
Other Platform Open
7%
Closed
36%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 45%
65
Hybrid 32%
45
No Guarantees 23%
33
Other Platform Open
Domain 80%
81
Institution 29%
29
Other Internet 15%
15
Preprint 5%
5
Public 1%
1
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 81 |
DOI | Other Internet | 12 |
Unknown Repository | Other Internet | 5 |
University of Milano-Bicocca | Institution | 4 |
Le Centre pour la Communication Scientifique Directe - HAL - Diderot | Institution | 4 |
Imperial College London | Institution | 3 |
University of Udine | Institution | 2 |
University of Oxford | Institution | 2 |
University of Milan | Institution | 2 |
University of Groningen | Institution | 2 |